Meningococcal (muh-nin-jo-cok-ul) disease is a serious bacterial infection that most often leads to severe swelling of the tissues surrounding the brain and spinal cord (meningitis) or infection of the bloodstream (meningococcemia). Even with treatment, approximately one out of every 10 people who get meningococcal disease will die; of those who survive, about two in 10 will have permanent problems including brain damage, kidney damage, hearing loss, or amputation of arms, legs, fingers, or toes.
NFID is committed to increasing awareness about meningococcal disease among consumers and healthcare professionals and to prevention of meningococcal disease through vaccination.
- Routine vaccination with a quadrivalent vaccine that protects against four major meningococcal serogroups (A, C, W, and Y) is recommended for all adolescents at age 11-12 years with a booster dose at age 16 years.
- Meningococcal serogroup B vaccination may be recommended by healthcare professionals for certain individuals age 16-23 years, with a preferred age of 16-18 years. Learn more about serogroup B disease, vaccine insurance coverage, and recent outbreaks on US college campuses.
Talk to your healthcare professional to make sure that your child is fully protected against all serogroups of this deadly disease.
Learn more about meningococcal disease and the vaccines to prevent it in adolescents at adolescentvaccination.org
and adults at adultvaccination.org